<table id="ID755" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3: Clinically Significant Drug Interactions with Celecoxib</caption>
<col width="25%"></col>
<col width="75%"></col>
<tbody>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Drugs </content>
<content stylecode="bold">That </content>
<content stylecode="bold">Interfere </content>
<content stylecode="bold">with </content>
<content stylecode="bold">Hemostasis</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">•  Celecoxib and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of celecoxib and anticoagulants have an increased risk of serious bleeding compared to the <br/>use of either drug alone. <br/>
<br/>•  Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an<br/>NSAID may potentiate the risk of bleeding more than an NSAID alone.<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">•  Monitor patients with concomitant use of celecoxib with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine  reuptake inhibitors (SNRIs) for signs of bleeding [see WARNINGS AND PRECAUTIONS (<linkhtml href="#ID717">5.11</linkhtml>)]. </td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Aspirin</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">•  Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study,  the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see WARNINGS AND  PRECAUTIONS (<linkhtml href="#ID692">5.2</linkhtml>)].   In two studies in healthy volunteers, and in patients with osteoarthritis and established heart disease respectively, celecoxib capsules (200 to 400 mg daily) has demonstrated a lack of interference  with the cardioprotective antiplatelet effect of aspirin (100 to 325 mg). </td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concomitant use of celecoxib and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see WARNINGS AND PRECAUTIONS (<linkhtml href="#ID717">5.11</linkhtml>)].  Celecoxib capsules are not a substitute for low dose aspirin for cardiovascular protection. </td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">ACE </content>
<content stylecode="bold">Inhibitors</content>
<content stylecode="bold">, </content>
<content stylecode="bold">Angiotensin </content>
<content stylecode="bold">Receptor </content>
<content stylecode="bold">Blockers</content>
<content stylecode="bold">, </content>
<content stylecode="bold">and </content>
<content stylecode="bold">Beta</content>
<content stylecode="bold">-</content>
<content stylecode="bold">Blockers</content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">•  NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol). <br/>•  In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration <br/>of renal function, including possible acute renal failure. These effects are usually reversible.<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">•  During concomitant use of celecoxib and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.  •  During concomitant use of celecoxib and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see WARNINGS AND PRECAUTIONS (<linkhtml href="#ID704">5.6</linkhtml>)].  •  When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter. </td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Diuretics</content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. <br/>This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">During concomitant use of celecoxib with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects  [see WARNINGS AND PRECAUTIONS (<linkhtml href="#ID704">5.6</linkhtml>)]. </td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Digoxin</content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">The concomitant use of celecoxib with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">During concomitant use of celecoxib and digoxin, monitor serum digoxin levels.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Lithium</content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by <br/>approximately 20%.<br/>This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">During concomitant use of celecoxib and lithium, monitor patients for signs of lithium toxicity.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Methotrexate</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). <br/>
<br/>Celecoxib capsules has no effect on methotrexate pharmacokinetics.<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">During concomitant use of celecoxib and methotrexate, monitor patients for methotrexate toxicity.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Cyclosporine</content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concomitant use of celecoxib and cyclosporine may increase cyclosporine’s nephrotoxicity.<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">During concomitant use of celecoxib and cyclosporine, monitor patients for signs of worsening renal function.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">NSAIDs </content>
<content stylecode="bold">and </content>
<content stylecode="bold">Salicylates</content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concomitant use of celecoxib with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy  [see WARNINGS AND PRECAUTIONS (<linkhtml href="#ID692">5.2</linkhtml>)]. </td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">The concomitant use of celecoxib with other NSAIDs or salicylates is not recommended.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Pemetrexed</content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concomitant use of celecoxib and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">During concomitant use of celecoxib and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. <br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. <br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing <br/>for at least five days before, the day of, and two days following pemetrexed administration.<br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">CYP2C9 </content>
<content stylecode="bold">Inhibitors </content>
<content stylecode="bold">or </content>
<content stylecode="bold">inducers</content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Celecoxib metabolism is predominantly mediated via cytochrome P450 (CYP) 2C9 in the liver. Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g. fluconazole) may <br/>enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of celecoxib.<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Evaluate each patient's medical history when consideration is given to prescribing celecoxib. A dosage adjustment may be warranted when celecoxib is administered with CYP2C9 inhibitors or inducers.  [see CLINICAL PHARMACOLOGY (<linkhtml href="#ID791">12.3</linkhtml>)]. </td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">CYP2D6 </content>
<content stylecode="bold">substrates</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">In </content>
<content stylecode="italics">vitro </content>studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an <content stylecode="italics">in </content>
<content stylecode="italics">vivo </content>drug interaction with drugs that are metabolized by CYP2D6 <br/>(e.g. atomoxetine), and celecoxib may enhance the exposure and toxicity of these drugs.<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Evaluate each patient's medical history when consideration is given to prescribing celecoxib. A dosage adjustment may be warranted when celecoxib is administered with CYP2D6 substrates.  [see CLINICAL PHARMACOLOGY (<linkhtml href="#ID791">12.3</linkhtml>)]. </td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Corticosteroids </content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concomitant use of corticosteroids with celecoxib capsules may increase the risk of GI ulceration or bleeding.<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor patients with concomitant use of celecoxib capsules with corticosteroids for signs of bleeding [see WARNINGS AND PRECAUTIONS (<linkhtml href="#ID692">5.2</linkhtml>)]. </td>
</tr>
</tbody>
</table>